Literature DB >> 33859803

Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Wuqing Deng1, Xiaojuan Chen2, Kaili Jiang1, Xiaojuan Song3, Minhao Huang3, Zheng-Chao Tu3, Zhang Zhang1, Xiaojing Lin4, Raquel Ortega4, Adam V Patterson5,4, Jeff B Smaill5,4, Ke Ding1, Suming Chen6, Yongheng Chen2, Xiaoyun Lu1.   

Abstract

Covalent kinase inhibitors are rapidly emerging as a class of therapeutics with clinical benefits. Herein we report a series of selective 2-aminopyrimidine-based fibroblast growth factor receptor 4 (FGFR4) inhibitors exploring different types of cysteine-targeting warheads. The structure-activity relationship study revealed that the chemically tuned warheads α-fluoro acrylamide, vinylsulfonamide, and acetaldehyde amine were suitable as covalent warheads for the design of selective FGFR4 inhibitors. Compounds 6a, 6h, and 6i selectively suppressed FGFR4 enzymatic activity with IC50 values of 53 ± 18, 45 ± 11, and 16 ± 4 nM, respectively, while sparing FGFR1/2/3. X-ray crystal structure and MALDI-TOF studies demonstrated that compound 6h bearing the α-fluoro acrylamide binds to FGFR4 with an irreversible binding mode, whereas compound 6i with an acetaldehyde amine binds to FGFR4 with a reversible covalent mode. 6h and 6i might provide some fundamental structural information for the rational design of new selective FGFR4 inhibitors.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33859803      PMCID: PMC8040253          DOI: 10.1021/acsmedchemlett.1c00052

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  20 in total

1.  Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.

Authors:  Xiaoyun Lu; Hao Chen; Adam V Patterson; Jeff B Smaill; Ke Ding
Journal:  J Med Chem       Date:  2018-11-16       Impact factor: 7.446

2.  First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Authors:  Richard D Kim; Debashis Sarker; Tim Meyer; Thomas Yau; Teresa Macarulla; Joong-Won Park; Su Pin Choo; Antoine Hollebecque; Max W Sung; Ho-Yeong Lim; Vincenzo Mazzaferro; Joerg Trojan; Andrew X Zhu; Jung-Hwan Yoon; Sunil Sharma; Zhong-Zhe Lin; Stephen L Chan; Sandrine Faivre; Lynn G Feun; Chia-Jui Yen; Jean-Francois Dufour; Daniel H Palmer; Josep M Llovet; Melissa Manoogian; Meera Tugnait; Nicolas Stransky; Margit Hagel; Nancy E Kohl; Christoph Lengauer; Cori Ann Sherwin; Oleg Schmidt-Kittler; Klaus P Hoeflich; Hongliang Shi; Beni B Wolf; Yoon-Koo Kang
Journal:  Cancer Discov       Date:  2019-10-01       Impact factor: 39.397

Review 3.  Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.

Authors:  Xiaoyun Lu; Jeff B Smaill; Ke Ding
Journal:  J Med Chem       Date:  2020-06-02       Impact factor: 7.446

Review 4.  Cellular signaling by fibroblast growth factor receptors.

Authors:  V P Eswarakumar; I Lax; J Schlessinger
Journal:  Cytokine Growth Factor Rev       Date:  2005-02-01       Impact factor: 7.638

5.  2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

Authors:  Cheng Mo; Zhang Zhang; Christopher P Guise; Xueqiang Li; Jinfeng Luo; Zhengchao Tu; Yong Xu; Adam V Patterson; Jeff B Smaill; Xiaomei Ren; Xiaoyun Lu; Ke Ding
Journal:  ACS Med Chem Lett       Date:  2017-03-31       Impact factor: 4.345

6.  Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.

Authors:  Xiaojing Lin; Yuliana Yosaatmadja; Maria Kalyukina; Martin J Middleditch; Zhen Zhang; Xiaoyun Lu; Ke Ding; Adam V Patterson; Jeff B Smaill; Christopher J Squire
Journal:  ACS Med Chem Lett       Date:  2019-07-03       Impact factor: 4.345

7.  2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4.

Authors:  Thomas Knoepfel; Pascal Furet; Robert Mah; Nicole Buschmann; Catherine Leblanc; Sebastien Ripoche; Diana Graus-Porta; Markus Wartmann; Inga Galuba; Robin A Fairhurst
Journal:  ACS Med Chem Lett       Date:  2018-02-01       Impact factor: 4.345

8.  Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

Authors:  Robin A Fairhurst; Thomas Knoepfel; Nicole Buschmann; Catherine Leblanc; Robert Mah; Milen Todorov; Pierre Nimsgern; Sebastien Ripoche; Michel Niklaus; Nicolas Warin; Van Huy Luu; Mario Madoerin; Jasmin Wirth; Diana Graus-Porta; Andreas Weiss; Michael Kiffe; Markus Wartmann; Jacqueline Kinyamu-Akunda; Dario Sterker; Christelle Stamm; Flavia Adler; Alexandra Buhles; Heiko Schadt; Philippe Couttet; Jutta Blank; Inga Galuba; Jörg Trappe; Johannes Voshol; Nils Ostermann; Chao Zou; Jörg Berghausen; Alberto Del Rio Espinola; Wolfgang Jahnke; Pascal Furet
Journal:  J Med Chem       Date:  2020-10-01       Impact factor: 7.446

9.  Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

Authors:  Robin A Fairhurst; Thomas Knoepfel; Catherine Leblanc; Nicole Buschmann; Christoph Gaul; Jutta Blank; Inga Galuba; Jörg Trappe; Chao Zou; Johannes Voshol; Christine Genick; Peggy Brunet-Lefeuvre; Francis Bitsch; Diana Graus-Porta; Pascal Furet
Journal:  Medchemcomm       Date:  2017-06-08       Impact factor: 3.597

Review 10.  Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma.

Authors:  Dimitra Repana; Paul Ross
Journal:  Diseases       Date:  2015-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.